Skip to main content

Table 1 Demographic data, stage, primary tumor histology and type of first CPI treatment

From: Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma

 All patients
(n = 428)
Ongoing CR
(n = 77)
Died < 6 months
(n = 69)
No local therapy**
(n = 230)
NED or NPRD
(n = 52)
Median age (IQR)65 (55 – 74)68 (55 – 75)65 (58 – 74)64 (55 – 74)61 (54 – 70)
Gender63% male68% male67% male61% male62% male
Stage before CPI
 Stage M1a (%)
 Stage M1b (%)
 Stage M1c (%)
 Stage M1d (%)
99 (23%)
90 (21%)
152 (36%)
87 (20%)
22 (29%)
21 (27%)
31 (40%)
3 (4%)
11 (16%)
8 (12%)
36 (52%)
14 (20%)
55 (24%)
53 (23%)
69 (30%)
53 (23%)
11 (21%)
8 (15%)
16 (31%)
17 (33%)
Sun-shielded*93 (22%)5 (6%)19 (28%)54 (23%)15 (29%)
1st Therapy (%)
 CTLA4
 PD1 or PDL1
 CTLA4 + PD1
124 (29%)
129 (30%)
175 (41%)
11 (14%)
23 (30%)
43 (56%)
28 (41%)
23 (33%)
18 (26%)
69 (30%)
71 (31%)
90 (39%)
16 (31%)
12 (23%)
24 (46%)
  1. Abbreviations: CR = complete response; IQR = interquartile range; NED = no evidence of disease; NPRD = non-progressive residual disease
  2. Stage M1a = distant metastases to skin or lymph nodes. Stage M1b = metastases to lung with or without M1a metastases. Stage M1c = metastases to visceral sites with or without M1a or M1b. Stage M1d = metastases to CNS with or without extra-cranial metastasis [20]
  3. *Sun-shielded melanomas include mucosal, ocular, perineal, and acral lentiginous
  4. **Some patients had procedures that did not meet inclusion criteria